AMPHASTAR PHARMACEUTICALS IN
AMPHNASDAQTrading Snapshot
- Day Range
- $26.50 β $27.18
- 52-Week Range
- $16.65 β $29.52
- Volume
- $2.93B
- Avg Volume
- $2.62B
- Shares Outstanding
- 44.1M
- Next Earnings
- Dec 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $720M
- Last Q Revenue
- $184M
- P/E Ratio
- 15.7
- P/S Ratio
- 1.7x
- EPS (TTM)
- $1.80
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β9.4%
Why Investors Own AMPH
- βHigh-growth profile β revenue up +25.4% YoY with expanding US Equity exposure.
- βHealthy economics β 29% gross margin and 7% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
AMPHASTAR PHARMACEUTICALS IN
AMPHAbout AMPHASTAR PHARMACEUTICALS IN
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Sells $239,400.00 in Stock
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) EVP Rong Zhou sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an a

Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc.Β (NASDAQ: AMPH)Β announced today thatΒ Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be pre

3 Generic Drug Stocks to Watch Amid Improving Industry Trends
The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.

New Strong Sell Stocks for August 14th
AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript

Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the y